ProQR Therapeutics Management
Management criteria checks 2/4
ProQR Therapeutics' CEO is Daniel de Boer, appointed in Feb 2012, has a tenure of 11.17 years. total yearly compensation is €2.46M, comprised of 20.5% salary and 79.5% bonuses, including company stock and options. directly owns 0.87% of the company’s shares, worth MX$27.78M. The average tenure of the management team and the board of directors is 3.3 years and 5.8 years respectively.
Key information
Daniel de Boer
Chief executive officer
€2.5m
Total compensation
| CEO salary percentage | 20.5% |
| CEO tenure | 11.2yrs |
| CEO ownership | 0.9% |
| Management average tenure | 3.3yrs |
| Board average tenure | 5.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2022 | €2m | €504k | -€65m |
| Sep 30 2022 | n/a | n/a | -€72m |
| Jun 30 2022 | n/a | n/a | -€63m |
| Mar 31 2022 | n/a | n/a | -€63m |
| Dec 31 2021 | €2m | €449k | -€62m |
| Sep 30 2021 | n/a | n/a | -€57m |
| Jun 30 2021 | n/a | n/a | -€55m |
| Mar 31 2021 | n/a | n/a | -€43m |
| Dec 31 2020 | €3m | €449k | -€47m |
| Sep 30 2020 | n/a | n/a | -€52m |
| Jun 30 2020 | n/a | n/a | -€51m |
| Mar 31 2020 | n/a | n/a | -€58m |
| Dec 31 2019 | €2m | €449k | -€56m |
| Sep 30 2019 | n/a | n/a | -€51m |
| Jun 30 2019 | n/a | n/a | -€45m |
| Mar 31 2019 | n/a | n/a | -€40m |
| Dec 31 2018 | €1m | €445k | -€37m |
| Sep 30 2018 | n/a | n/a | -€35m |
| Jun 30 2018 | n/a | n/a | -€40m |
| Mar 31 2018 | n/a | n/a | -€44m |
| Dec 31 2017 | €1m | €353k | -€44m |
| Sep 30 2017 | n/a | n/a | -€41m |
| Jun 30 2017 | n/a | n/a | -€41m |
| Mar 31 2017 | n/a | n/a | -€39m |
| Dec 31 2016 | €827k | €429k | -€39m |
Compensation vs Market: Daniel's total compensation ($USD2.71M) is above average for companies of similar size in the MX market ($USD532.66K).
Compensation vs Earnings: Daniel's compensation has increased whilst the company is unprofitable.
CEO
Daniel de Boer (39 yo)
11.2yrs
Tenure
€2,464,000
Compensation
Mr. Daniel Anton de Boer has been the Chief Executive Officer and Member of Management Board at ProQR Therapeutics N.V. since February 21, 2012. He serves as Member of Strategic Advisory Board at Hybridize...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Independent Chairman of Supervisory Board | no data | €178.00k | 0.52% € 16.6m | |
| Founder | 11.2yrs | €2.46m | 0.87% € 27.8m | |
| Chief Corporate Development Officer | less than a year | €463.00k | 0.57% € 18.1m | |
| Co-Founder & Chief Scientific Officer | 11.2yrs | €34.00k | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| VP & Head of People and Operations | 3.3yrs | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Junior Financial Controller | no data | no data | no data |
3.3yrs
Average Tenure
52yo
Average Age
Experienced Management: PRQR N's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder & Independent Chairman of Supervisory Board | 9.3yrs | €178.00k | 0.52% € 16.6m | |
| Independent Member of Supervisory Board | 9.3yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Member of Supervisory Board | 8.6yrs | €156.00k | 0% € 0 | |
| Member of Scientific Advisory Board | 5.8yrs | no data | no data | |
| Independent Member of Supervisory Board & Chairman of Scientific Advisory Board | 6.8yrs | €163.00k | 0.076% € 2.4m | |
| Independent Supervisory Board Member | 3.9yrs | €153.00k | 0% € 0 | |
| Member of Scientific Advisory Board | 2.8yrs | no data | no data | |
| Member Scientific Advisory Board | 5yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.9yrs | no data | no data |
5.8yrs
Average Tenure
63.5yo
Average Age
Experienced Board: PRQR N's board of directors are considered experienced (5.8 years average tenure).